

**INDEPENDENT AUDITORS' REPORT
TO THE SHAREHOLDERS OF
SUN PHARMA DE MEXICO S.A. DE C.V.**

REPORT ON THE FINANCIAL STATEMENTS

We have audited the accompanying Financial Statements of **Sun Pharma de Mexico S.A. de C.V.** ("the Company") which comprise the Balance Sheet as at 31st December, 2019 and 2018, the Statement of Profit and Loss, the Statement of Changes in Stockholders' Equity and the Cash Flow Statement of the Company for the year ended on 31st December, 2019 and 2018, also a summary of the significant accounting policies and other explanatory information annexed there to.

MANAGEMENT'S RESPONSIBILITY FOR THE FINANCIAL STATEMENTS

The Company's Board of Directors is responsible for the preparation and fair presentation of the accompanying financial statements in accordance with the Mexican Financial Reporting Standards and the internal control that Management deems necessary to enable the preparation of financial statements free of material misstatement due to fraud or error.

AUDITOR'S RESPONSIBILITY

Our responsibility is to express an opinion on these accompanying financial statements based on our audits. We have conducted our audits in accordance with International Standards of Auditing. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain true assurance about whether the financial statements are free of material misstatement.

An audit involves the performing procedures to obtain audit evidence about the amounts and disclosures disclosed in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement in the financial statements whether due to fraud or error. In making such risk assessments, the auditor takes into account the internal control relevant to the preparation and faithful presentation by the Company of the financial statements in order to design audit procedures that are appropriate to the circumstances, and not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.

An audit also includes evaluating the accounting policies applied and the reasonableness of the accounting estimates made by the Board of Directors, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained provides a sufficient and adequate basis to support our opinion without fiscal qualification.

OPINION

In our opinion, the financial statements present fairly, in all material respects, the financial position of Sun Pharma de México, S.A. de C.V. as of December 31, 2019 and 2018 as well as its results, changes in stockholders' equity and their cash flows for the years then ended, in accordance with the Mexican Financial Reporting Standards.

OTHER MATTER

The financial statements for the year ended December 31, 2018 were also audited by this same firm of public accountants based on the Auditing Standards generally accepted in Mexico.

Garcia Landa Becerril & Asociados S.C.

**C.P.C. Jorge Marcos Garcia Landa
Independent Auditors
AGAFF Registration No. 03325
Mexico City, March 26, 2020**

**STATUTORY AUDITORS' REPORT
TO THE SHAREHOLDERS OF
SUN PHARMA DE MEXICO S.A. DE C.V.**

In my capacity as Statutory Auditor, and in compliance with the provisions of Article 166 of the Mexican General Corporations Law and the by-laws of **Sun Pharma de Mexico S.A. de C.V.** ("the Company"), I am pleased to submit my Audit Report on the veracity, sufficiency and reasonability of the Financial Statements of the Company for the year ended December 31, 2019, presented to you by the Board of Directors of the Company.

I have attended the Shareholders' and the Board of Directors' meetings to which I was summoned and I have obtained from the board members and the Company's officers all the information on the Company's operations, documentation and records, that I considered necessary for examination. I conducted my audit in accordance with auditing standards generally accepted in Mexico.

In my opinion, the accounting and reporting policies and procedures observed by the Company in the preparation of the financial statements that are being presented to the shareholders are adequate and sufficient and were applied on a basis consistent with that of the previous year. Therefore, it is also my opinion that the financial statements referred to above give a True and Fair view in conformity with Mexican Financial Reporting Standards:

- i. In the case of Balance Sheet, of the state of affairs of the Company as at December 31, 2019;
- ii. In the case of Statement of Profit and Loss, of the profit of the Company for the year ended on that date;
- iii. In the case of Cash Flow Statement, of the cash flows of the Company for the year ended on that date; and
- iv. In the case of Statement of Changes in Stockholders' Equity, of the changes, if any, in stockholders' equity of the Company for the year ended on that date.

C.P.C. Jorge Daniel García Becerril
Statutory Auditor

Mexico City, March 26, 2020

SUN PHARMA DE MEXICO S.A. DE C.V.
BALANCE SHEET AS AT DECEMBER 31, 2019

	Notes	As at December 31, 2019		As at December 31, 2018	
		Mexican Pesos	Mexican Pesos	Mexican Pesos	Mexican Pesos
EQUITY AND LIABILITIES					
Shareholders' Funds					
Capital Stock		\$1,010,360		\$1,010,360	
Reserves and Surplus	5	<u>\$310,319,252</u>	<u>\$311,329,612</u>	<u>\$263,800,372</u>	\$264,810,732
Current Liabilities					
Trade Payables	6	\$20,143,785		\$11,674,305	
Other Current Liabilities	7	<u>\$3,735,888</u>	<u>\$23,879,673</u>	<u>\$10,823,076</u>	\$22,497,381
Total			<u><u>\$335,209,285</u></u>	<u><u>\$287,308,113</u></u>	
ASSETS					
Non Current Assets					
Fixed Assets					
Tangible Assets	23		\$23,104,450		\$21,058,871
Deferred Tax Assets (Net)			\$5,576,381		\$146,975
Current Assets					
Inventories	8	\$68,107,795		\$76,445,021	
Trade Receivables	9	\$71,655,823		\$74,930,048	
Cash and Cash Equivalents	10	\$151,118,263		\$90,821,527	
Short Term Loans and Advances	11	\$15,466,667		\$23,704,765	
Other Current Assets	12	<u>\$179,906</u>	<u>\$306,528,454</u>	<u>\$200,906</u>	\$266,102,267
Total			<u><u>\$335,209,285</u></u>	<u><u>\$287,308,113</u></u>	

See accompanying notes forming part of the Financial Statements

In terms of my/our report attached.

For and on behalf of the Board of Directors

C.P.C. Jorge Daniel García Becerril
Statutory Auditor

Lic. Fernando Salvador Ramos Suarez
President

For and on behalf of
Garcia Landa Becerril & Asociados S.C.

Lic. Vipulkumar Jayantilal Timbadia
Director

C.P.C. Jorge Marcos Garcia Landa
Independent Auditors

Mexico City, March 26, 2020

SUN PHARMA DE MEXICO S.A. DE C.V.

STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED DECEMBER 31, 2019

	Notes	Year Ended December 31, 2019		Year Ended December 31, 2018	
		Mexican Pesos	Mexican Pesos	Mexican Pesos	Mexican Pesos
Revenue From Operations	13		\$301,848,283		\$350,408,165
Other Income	14		\$13,070,265		\$12,035,937
Total Income			<u>\$314,918,548</u>		<u>\$362,444,102</u>
Cost of Materials Consumed	15	\$11,386,914		\$13,441,734	
Purchase of Stock-in-Trade	16	\$72,640,184		\$110,452,182	
Changes in Inventories of Finished Goods, Stock-in-Trade and Work-in-Progress	17	\$3,425,988		(\$25,822,069)	
Manufacturing Expenses	18	<u>6,635,922</u>	<u>\$94,089,008</u>	<u>10,042,998</u>	<u>\$108,114,845</u>
			<u>\$220,829,540</u>		<u>\$254,329,257</u>
Operational Expenses					
Personnel Expenses	19	\$64,982,003		\$68,375,695	
Marketing Sales and Distribution Expenses	20	\$52,562,822		\$52,540,707	
Other Expenses	21	\$34,322,916		\$24,662,849	
Depreciation	23	<u>\$4,953,546</u>	<u>\$156,821,287</u>	<u>\$5,117,693</u>	<u>\$150,696,944</u>
Operating Profit			<u>\$64,008,253</u>		<u>\$103,632,313</u>
Exchange Gain / (Loss) - Net			\$1,117,686		(\$470,733)
Profit Before Tax			\$65,125,939		\$103,161,580
Tax Expenses					
Current Tax		\$24,036,465		\$29,066,158	
Deferred Tax Expenses		<u>(\$5,429,406)</u>	<u>\$18,607,059</u>	<u>\$317,150</u>	<u>\$29,383,308</u>
Profit for the Year			<u><u>\$46,518,880</u></u>		<u><u>\$73,778,272</u></u>

See accompanying notes forming part of the Financial Statements

In terms of my/our report attached.

For and on behalf of the Board of Directors

C.P.C. Jorge Daniel García Becerril
Statutory Auditor

Lic. Fernando Salvador Ramos Suarez
President

For and on behalf of
Garcia Landa Becerril & Asociados S.C.

Lic. Vipulkumar Jayantilal Timbadia
Director

C.P.C. Jorge Marcos Garcia Landa
Independent Auditors

Mexico City, March 26, 2020

SUN PHARMA DE MEXICO S.A. DE C.V.

CASH FLOW STATEMENT FOR THE YEAR ENDED DECEMBER 31, 2019

	Year Ended December 31, 2019		Year Ended December 31, 2018	
	Mexican Pesos	Mexican Pesos	Mexican Pesos	Mexican Pesos
CASH FLOW FROM OPERATING ACTIVITIES				
Profit Before Tax		\$65,125,939		\$103,161,580
Adjustment for:				
Depreciation Expenses	\$4,953,546		\$5,117,693	
Provision for Doubtful Trade Receivables and Advances	\$2,147,662		\$321,799	
Profit on Sales of Fixed Assets	(\$2,025,402)		(\$2,818,857)	
Interest Income	(\$10,235,863)	(\$5,160,057)	(\$6,827,680)	(\$4,207,045)
Operating Profit Before Working Capital Changes		<u>\$59,965,882</u>		<u>\$98,954,535</u>
Changes in Working Capital:				
Increase / (Decrease) Trade Payables	\$8,469,480		(\$13,132,390)	
Increase / (Decrease) Other Current Liabilities	(\$7,087,188)		\$4,184,411	
Increase / (Decrease) Other Current Liabilities-Dividend Payable	\$0		(\$59,690,573)	
(Increase) / Decrease Inventories	\$8,337,226		(\$29,552,553)	
(Increase) / Decrease Trade Receivables	\$1,126,560		\$14,521,175	
(Increase) / Decrease Short Term Loans and Advances	\$8,238,098		(\$4,430,737)	
(Increase) / Decrease Other Current Assets	\$21,000	\$19,105,176	\$0	(\$88,100,667)
Cash Generated from Operations		<u>\$79,071,058</u>		<u>\$10,853,868</u>
Income Tax Paid		\$24,036,465		\$29,066,158
Net Cash Flow from Operating Activities		<u>\$55,034,593</u>		<u>(\$18,212,290)</u>
CASH FLOW FROM INVESTING ACTIVITIES				
Capital Expenditure on Fixed Assts (Net)		(\$7,016,210)		(\$9,826,055)
Proceed from Sales of Fixed Assets		\$2,042,490		\$2,913,200
Interest Income		\$10,235,863		\$6,827,680
Net Cash Flow Generated from / (Used in) Investing Activities		<u>\$5,262,143</u>		<u>(\$85,175)</u>
NET INCREASE IN CASH AND EQUIVALENTS		\$60,296,736		(\$18,297,465)
CASH AND EQUIVALENTS AT BEGINNING OF THE YEAR		\$90,821,527		\$109,118,992
CASH AND EQUIVALENTS AT END OF THE YEAR		<u>\$151,118,263</u>		<u>\$90,821,527</u>

See accompanying notes forming part of the Financial Statements

In terms of my/our report attached.

For and on behalf of the Board of Directors

C.P.C. Jorge Daniel García Becerril
Statutory Auditor

Lic. Fernando Salvador Ramos Suarez
President

For and on behalf of
García Landa Becerril & Asociados S.C.

Lic. Vipulkumar Jayantilal Timbadia
Director

C.P.C. Jorge Marcos García Landa
Independent Auditors

Mexico City, March 26, 2020

SUN PHARMA DE MEXICO S.A. DE C.V.

STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY YEAR ENDED DECEMBER 31, 2019

Shareholders' Name	Opening Balance		Addition / (Deletion)		Closing Balance	
	No. of Shares	Mexican Pesos	No. of Shares	Mexican Pesos	No. of Shares	Mexican Pesos
Sun Pharmaceutical Industries Ltd.	750	\$757,770	\$0	\$0	750	\$757,770
Indi Pharma SAPI de CV.	250	\$252,590	\$0	\$0	250	\$252,590
Total Capital Stock	1,000	\$1,010,360	\$0	\$0	1,000	\$1,010,360
Year ended December 31, 2018	1,000	\$1,010,360	\$0	\$0	1,000	\$1,010,360

See accompanying notes forming part of the Financial Statements

In terms of my/our report attached.

For and on behalf of the Board of Directors

C.P.C. Jorge Daniel García Becerril
Statutory Auditor

Lic. Fernando Salvador Ramos Suarez
President

For and on behalf of
Garcia Landa Becerril & Asociados S.C.

Lic. Vipulkumar Jayantilal Timbadia
Director

C.P.C. Jorge Marcos Garcia Landa
Independent Auditors

Mexico City, March 26, 2020

SUN PHARMA DE MEXICO S.A. DE C.V.

SIGNIFICANT ACCOUNTING POLICIES AND NOTES TO FINANCIAL STATEMENTS

A. PRESENTATION:

Sun Pharma de Mexico S.A. de C.V. is a Mexican Company incorporated on December 3, 2002 under the Mexican laws with a foreign investor, the Company is involved in business of Pharmaceutical Products.

B. SIGNIFICANT ACCOUNTING POLICIES:

I. Basis of Accounting

These financial statements are prepared under historical cost convention on an accrual basis in accordance with the Generally Accepted Accounting Principles in Mexico and Mexican Financial Reporting Standards (Mexican FRS) as issued by CINIF (Consejo Mexicano para la Investigación y Desarrollo de Normas de Información Financiera, A.C.), the Financial Statements are presented in Mexican pesos.

II. Use of Estimates

The presentation of financial statements in conformity with the generally accepted accounting principles requires estimates and assumptions to be made that affect the reported amount of assets and liabilities on the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Difference between the actual result and estimates are recognized in the period in which the results are known/materialized.

III. Property, plant and equipment

Recognition and measurement

Items of property, plant and equipment are measured at cost less accumulated depreciation and accumulated impairment losses, if any. Cost includes expenditures that are directly attributable to the acquisition of the asset.

Gains and losses upon disposal of an item of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of property, plant and equipment and are recognized net within "other (income)/expense, net" in the income statement.

The cost of replacing part of an item of property, plant and equipment is recognized in the carrying amount of the item if it is probable that the future economic benefits embodied within the part will flow to the Company and its cost can be measured reliably. The costs of repairs and maintenance are recognized in the income statement as incurred.

Depreciation

Depreciation is recognized in the income statement on a straight line basis over the estimated useful lives of property, plant and equipment at the rates specified under the Mexican Tax Laws. Land is not depreciated. Depreciation methods, useful lives and residual values are reviewed at each reporting date.

IV. Revenue Recognition

Sale of goods Revenue is recognized when the significant risks and rewards of ownership have been transferred to the buyer, recovery of the consideration is probable, the associated costs and possible return of goods can be estimated reliably, there is no continuing management involvement with the goods and the amount of revenue can be measured reliably. Revenue from the sale of goods includes VAT, if any, and is measured at the fair value of the consideration received or receivable, net of returns and applicable trade discounts and allowances.

V. Inventories

Inventories consist of raw materials, stores and spares, work in progress and finished goods and are measured at the lower of cost and net realizable value. The cost of all categories of inventories is based on the weighted average method. Cost includes expenditures incurred in acquiring the inventories, production or conversion costs and other costs incurred in bringing them to their existing location and condition. In the case of finished goods and work in progress, cost includes an appropriate share of overheads based on normal operating capacity.

Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and selling expenses.

VI. Foreign Currency Transactions

Transactions in foreign currencies are translated to the respective functional currency at exchange rates at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies at the reporting date are translated into the functional currency at the exchange rate at that date. Exchange differences arising on the settlement of monetary items or on translating monetary items at rates different from those at which they were translated on initial recognition during the period or in previous financial statements are recognized in the consolidated income statement in the period in which they arise.

VII. Effects of Inflation

As defined under Mexican FRS B-10, Effects of Inflation, the Company is considered to operate in a non-inflationary environment and accordingly, the Company presents its financial information in nominal Mexican pesos.

VIII. Income tax

Income tax expense consists of current and deferred tax. Income tax expense is recognized in the income statement. Current tax is the expected tax payable on the taxable income for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to tax payable in respect of previous years.

Deferred tax is recognized using the balance sheet method, providing for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is measured at the tax rates that are expected to be applied to the temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date.

IX. Provisions, Contingent Liabilities and Contingent Assets

A provision is recognized if, as a result of a past event, the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation.

Contingent liability is disclosed for (i) Possible obligations which will be confirmed only by future events not wholly within the control of the company or (ii) Present obligations arising from past events where it is not probable that an outflow of resources will be required to settle the obligation or a reliable estimate of the amount of the obligation cannot be made. Contingent Assets are not recognized in the financial statements since this may result in the recognition of income that may never be realized.

C. NOTES TO FINANCIAL STATEMENTS:

1. Capital Stock

As at December 31, 2019, the Fixed Capital Stock represents an amount of \$1,010,360 Mexican Pesos (Previous Year \$1,010,360 Mexican Pesos), represented by 1,000 (Previous Year 1,000) Ordinary and Nominative Shares with no par value.

2. Legal Reserve

In accordance with the requirements of Mexican General Corporations Law and the By-laws of the Company of creating Legal Reserve of 5% of Capital Stock, the Company, in the year 2012, has created Legal Reserve of \$202,072 Mexican Pesos out of the Accumulated Profits.

	As at December 31, 2019		As at December 31, 2018	
	U.S. Dollars	Mexican Pesos	U.S. Dollars	Mexican Pesos
3. Foreign Currency Assets and Liabilities Position				
a) Foreign Currency Assets				
Bank Balance	\$1,199	\$22,634	\$8,583	\$168,705
b) Foreign Currency Liabilities				
Trade Payables	\$342,842	\$6,470,355	\$42,869	\$842,657
4. Balances Payable to and Operations with Related Parties				
a) Balances Payable				
Sun Pharmaceuticals Industries Ltd.		\$6,286,602		\$0
Endesk Servicios S.A. de C.V.		\$0		\$42,101
b) Operations				
Purchases / Expenses				
Sun Pharmaceuticals Industries Ltd.		\$85,869,486		\$103,828,118
Endesk Servicios S.A de C.V.		\$74,711,612		\$79,153,384
5. Reserves and Surplus				
Legal Reserve:				
Opening / Closing Balance		\$202,072		\$202,072
Surplus in Statement of Profit and Loss				
Opening Balance				
Add: Profit For the Year	\$263,598,300		\$189,820,028	
	\$46,518,880	\$310,117,180	\$73,778,272	\$263,598,300
		<u>\$310,319,252</u>		<u>\$263,800,372</u>
6. Trade Payable				
Sundry Creditors		\$11,098,186		\$9,376,444
Expenses Payable		\$9,045,599		\$2,297,861
		<u>\$20,143,785</u>		<u>\$11,674,305</u>
7. Other Current Liabilities				
Advances Received		\$2,171,940		\$3,124,806
Tax Payable		\$1,531,615		\$7,661,140
Withholding Tax Payable		\$32,333		\$37,130
		<u>\$3,735,888</u>		<u>\$10,823,076</u>
8. Inventories				
(Valued at Lower of Cost or Net realisable value)				
Raw and Packing Materials		\$15,911,934		\$20,823,172
Work In Progress		\$146,134		\$840,883
Finished Goods	\$49,060,899		\$49,163,334	
Goods In Transit	\$2,988,828	\$52,049,727	\$5,617,632	\$54,780,966
		<u>\$68,107,795</u>		<u>\$76,445,021</u>
9. Trade Receivables				
(Unsecured)				
Considered good		\$71,655,823		\$74,930,048
Considered doubtful		\$18,138,918		\$15,991,256
		<u>\$89,794,741</u>		<u>\$90,921,304</u>
Less: Allowance for Doubtful debts		\$18,138,918		\$15,991,256
		<u>\$71,655,823</u>		<u>\$74,930,048</u>
10. Cash and Cash Equivalents				
Balances With Banks:				
On Current Peso Accounts	\$293,105		\$4,649,340	
On Current U.S. Dollar Account	\$22,634		\$168,705	
On Deposit Peso Accounts	\$150,786,524	\$151,102,263	\$85,987,482	\$90,805,527
Cash on Hand		\$16,000		\$16,000
		<u>\$151,118,263</u>		<u>\$90,821,527</u>
11. Short Term Loans and Advances				
(Unsecured-Considered Good unless specified otherwise)				
Advances for supply of goods and Services				
Considered Good	\$155,222		\$467,622	
Considered Doubtful	\$2,730,000		\$2,730,000	
	\$2,885,222		\$3,197,622	
Less : Allowance for doubtful Advances	(\$2,730,000)	\$155,222	(\$2,730,000)	\$467,622
Prepaid Expenses		\$2,705,371		\$3,277,499
Balances with Government Authorities		\$12,575,708		\$19,901,634
Interest Accrued		\$30,366		\$39,027
Others Advances		\$0		\$18,983
		<u>\$15,466,667</u>		<u>\$23,704,765</u>

12. Other Current Assets (Unsecured-Considered Good) Deposits Given	\$179,906	\$200,906
	<u>\$179,906</u>	<u>\$200,906</u>
	Year Ended December 31, 2019	Year Ended December 31, 2018
	Mexican Pesos	Mexican Pesos
13. Revenue from Operations Net Sales	\$301,848,283	\$350,408,165
	<u>\$301,848,283</u>	<u>\$350,408,165</u>
14. Other Income Interest Profit on Sales of Fixed Assets Insurance Claims Received Other Miscellaneous Income	\$10,235,863 \$2,025,402 \$674,834 \$134,166	\$6,827,680 \$2,818,857 \$2,148,886 \$240,514
	<u>\$13,070,265</u>	<u>\$12,035,937</u>
15. Cost of Materials Consumed Raw and packing materials: Inventories at the beginning of the year Purchases during the year Inventories at the end of the year	\$20,823,172 \$6,475,676 (\$15,911,934)	\$17,092,688 \$17,172,218 (\$20,823,172)
	<u>\$11,386,914</u>	<u>\$13,441,734</u>
16. Purchases of Stock-in-Trade Purchases of Trading Goods	\$72,640,184	\$110,452,182
	<u>\$72,640,184</u>	<u>\$110,452,182</u>
17. Changes in Inventories of Finished Goods, Stock-in-Trade and Work-in-Progress Inventories at the beginning of the year Inventories at the end of the year	\$55,621,849 (\$52,195,861)	\$29,799,780 (\$55,621,849)
	<u>\$3,425,988</u>	<u>(\$25,822,069)</u>
18. Manufacturing Expenses Conversion Charges	\$6,635,922	\$10,042,998
	<u>\$6,635,922</u>	<u>\$10,042,998</u>
19. Personnel Expenses Salaries, Wages, Bonus and Benefits Staff Welfare Expenses	\$64,431,390 \$550,613	\$67,843,258 \$532,437
	<u>\$64,982,003</u>	<u>\$68,375,695</u>
20. Marketing, Sales and Distribution Expenses Marketing and Sales Expenses Samples Logistics and Distribution Special Discounts Field Staff Incentives	\$18,103,217 \$17,485,985 \$6,336,962 \$6,939,011 \$3,697,647	\$17,911,971 \$18,343,355 \$6,387,085 \$4,983,105 \$4,915,191
	<u>\$52,562,822</u>	<u>\$52,540,707</u>
21. Other Expenses Power and Fuel Rent Rates and Taxes Consumption of Lab Chemicals, Stores etc. Repairs and Maintenance Insurance Printing and Stationery Membership Fees Traveling Lodging and Boarding Vehicle Running Expenses Communications Consulting Fees Audit Fees Provision for Doubtful Trade Receivables and Advances Regulatory Related Study Charges Regulatory Filing Fees Other Regulatory Expenses Other Misc. Expenses	\$437,537 \$1,273,810 \$87,680 \$2,048,363 \$325,199 \$4,160,859 \$225,995 \$604,399 \$4,895,904 \$4,862,315 \$705,589 \$653,412 \$104,780 \$2,147,662 \$7,760,860 \$963,344 \$1,462,158 \$1,603,050	\$421,869 \$1,457,670 \$84,139 \$2,367,684 \$368,363 \$3,381,396 \$180,389 \$586,178 \$4,110,327 \$4,774,443 \$765,909 \$556,748 \$98,850 \$321,799 \$403,000 \$979,638 \$2,193,991 \$1,610,456
	<u>\$34,322,916</u>	<u>\$24,662,849</u>

22. Previous years' Figures are regrouped/rearranged wherever necessary.

Particulars	Dep. Rate	Gross Block (At Cost)				Depreciation / Amortisation / Impairment			Net Block	
		As At 01.01.19	Additions During the Year	Deletions / Adjustments During the Year	As at 31.12.19	As at 01.01.19	Additions During the Year	Deletions / Adjustments During the Year	As at 31.12.19	As at 31.12.19
Tangible Assets										
Freehold Land	0%	\$5,245,942			\$5,245,942	\$0	\$0	\$0	\$5,245,942	\$5,245,942
Buildings	5%	\$5,296,665			\$5,296,665	\$264,833	\$3,049,518	\$3,049,518	\$2,247,147	\$2,247,147
Plant and Machinery	10%	\$37,895,051	\$56,279	\$0	\$37,951,330	\$638,777	\$34,324,305	\$34,324,305	\$3,627,025	\$4,209,523
Data Processing Equipments	30%	\$1,150,308	\$55,939	\$0	\$1,206,247	\$38,526	\$1,150,834	\$1,150,834	\$55,413	\$38,000
Office Equipments	10%	\$270,951	\$21,119	\$0	\$292,070	\$11,062	\$257,587	\$257,587	\$34,483	\$24,426
Vehicles	25%	\$16,644,338	\$6,882,873	(\$4,753,711)	\$18,773,500	\$3,724,473	\$7,199,670	\$7,199,670	\$11,573,830	\$8,432,515
Electrical Fittings	10%	\$117,641			\$117,641	\$9,565	\$117,641	\$117,641	\$0	\$9,565
Furniture and Fixtures	10%	\$3,375,099			\$3,375,099	\$266,310	\$3,054,489	\$3,054,489	\$320,610	\$586,920
Total		\$69,995,995	\$7,016,210	(\$4,753,711)	\$72,258,494	\$48,937,124	\$4,953,546	(\$4,736,626)	\$49,154,044	\$23,104,450
Previous Year 2018		\$66,896,022	\$9,826,055	(\$6,726,082)	\$69,995,995	\$50,451,170	\$5,117,693	(\$6,631,739)	\$48,937,124	\$21,058,871

23. FIXED ASSETS

Mexican Pesos